Adenovirus COVID-19 Vaccines: Challenges of Prior AD Immunity

Article

Dr. Patrick Soon-Shiong and Dr. Adam Brufsky move on from the messenger RNA candidates to the adenovirus vaccines.

Dr. Patrick Soon-Shiong and Dr. Adam Brufsky move on from the messenger RNA candidates to the adenovirus vaccines.

Dr. Soon-Shiong delves into some of his reasoning for the ImmunityBio vaccine candidate's particular orientation toward the immune system.

Newsletter

Stay ahead of emerging infectious disease threats with expert insights and breaking research. Subscribe now to get updates delivered straight to your inbox.

Subscribe Now!
Recent Videos
Related Content
Monoclonal Antibody Shows 84% Relative Risk Reduction of Symptomatic COVID-19 Vs Placebo

Monoclonal Antibody Shows 84% Relative Risk Reduction of Symptomatic COVID-19 Vs Placebo

John Parkinson
June 29th 2025
Article
Tailoring Therapies in Community Acquired Pneumonia in the Inpatient Setting

Tailoring Therapies in Community Acquired Pneumonia in the Inpatient Setting

George Sakoulas, MD
November 6th 2023
Podcast
Gates Foundation Pledges $1.6 Billion to Gavi, the Vaccine Alliance

Gates Foundation Pledges $1.6 Billion to Gavi, the Vaccine Alliance

John Parkinson
June 25th 2025
Article
ACIP Preferentially Recommends Fluzone High-Dose Influenza Vaccine for Seniors

ACIP Preferentially Recommends Fluzone High-Dose Influenza Vaccine for Seniors

Nina Cosdon
June 23rd 2022
Podcast
FDA Approves Gilead’s Twice-Yearly Injectable Lenacapavir (Yeztugo) for HIV Prevention

FDA Approves Gilead’s Twice-Yearly Injectable Lenacapavir (Yeztugo) for HIV Prevention

Sophia Abene;Jared Baeten, MD, PhD
June 18th 2025
Article
Estimate Suggests 30% of Americans Express Vaccine Skepticism

Estimate Suggests 30% of Americans Express Vaccine Skepticism

Sophia Abene
June 18th 2025
Article
© 2025 MJH Life Sciences

All rights reserved.